BioSpace News Archive

Pharm Country

Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Celmatix Inc.today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

June 27, 2023
·
4 min read
Business

Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors

Boston Scientific Corporation announced the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately.

June 27, 2023
·
2 min read
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing

Foresee Pharmaceuticals, announces that it has successfully completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of NT$75 per share.

June 27, 2023
·
2 min read
Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023

Promore Pharma Promore Pharma AB, reg. no. 556639-6809, held its AGM on Tuesday, 27 June 2023.

June 27, 2023
·
3 min read
Drug Development

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced initial clinical data from the dose escalation portion of the Phase 1 clinical study of BDTX-1535.

June 27, 2023
·
10 min read
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA

PharmaTher Holdings Ltd. is pleased to announce it has filed a Pre-Submission Facility Correspondence in advance of its Abbreviated New Drug Application (“ANDA”) for KETARX™ (racemic ketamine) to the Food and Drug Administration (“FDA”) to support expedited review of its priority ANDA.

June 27, 2023
·
4 min read
Business

ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis today announced that Cancer Focus Fund plans to invest $4.5 million to support the Phase 1a/1b clinical trial of ImmunoGenesis’ lead candidate, IMGS-001.

June 27, 2023
·
6 min read
FDA

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced RYSTIGGO® (rozanolixizumab-noli) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.1

June 27, 2023
·
17 min read
Business

Nevro to Report Second Quarter 2023 Financial Results

Nevro Corp. today announced that the company will report its financial results for the second quarter ended June 30, 2023 after the market closes on August 1, 2023.

June 27, 2023
·
2 min read
BioCapital

REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a virtual investor day on July 11, 2023.

June 27, 2023
·
5 min read